CLINICAL ROLE -
Adverse Effects Impact Treatment Selection for VEGF-Targeted Oral TKIs in Metastatic RCC
Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Read More
Oral Oncolytics Expand Armamentarium in HR+/HER– Early-Stage Breast Cancer in Adjuvant Setting
New agents can offer a more tailored approach to therapy selection.
Brown Bag Consult®: Melanoma
Melanoma is responsible for 80% of skin cancer deaths.